Global Genetic Analysis Market Size, Share Analysis Report, 2024-2032
Global Genetic Analysis Market Size, Share Analysis Report, 2024-2032

Genetic Analysis Market Share, Size, Trends, Industry Analysis Report, By Type (Predictive Genetic Testing, Carrier Testing, Prenatal and Newborn Testing, Disease Diagnostic Testing, Pharmacogenomic Testing, and Others); By Application; By Technology; By End-Use; By Region; Segment Forecast, 2024-2032

  • Published Date:Jan-2024
  • Pages: 116
  • Format: PDF
  • Report ID: PM3113
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

The global genetic analysis market was valued at USD 21.39 billion in 2023 and is expected to grow at a CAGR of 8.60% during the forecast period. Rapidly increasing prevalence for early & rapid diagnosis and extensive rise in the awareness & acceptance of a variety of personalized medicines, along with the higher technological advancements in genetic analysis techniques, are primary factors boosting the market growth. Moreover, the increasing government focus on regulating and creating awareness towards genetic tests worldwide, along with the growing innovations in product design, quality improvement, and making them easily available to all types of patients, are further anticipated to create huge growth opportunities over the coming years.

Genetic Analysis Market Size

Know more about this report: Request for sample pages

For instance, in January 2023, Genetic Analysis entered into a strategic agreement with Microbiome Research to launch a new test service portfolio based on GA-map Dysbiosis Test. The new service offering will target clinical research customers and medical customers.

Moreover, researchers worldwide are becoming more aware that the numerous geniting testing procedures, including cytogenetic, biochemical molecular, and DNA sequencing, provide the vision to make tailored illness treatments possible. Additionally, the demand for innovative genetic testing from patients to primary care physicians is anticipated to grow, especially from healthy adults seeking prevention for hereditary illnesses and early identification.

The outbreak of the COVID-19 pandemic has significantly impacted the growth of the genetic analysis market. To cater to the growing spread of the coronavirus, countries worldwide imposed lockdowns and many other restrictions on mass body movement that led to high disruptions, limitations, and challenges in each sector, including genetic testing. Genetic counselors could not easily see patients in person, and laboratories could not run the tests.

Genetic Analysis

Know more about this report: Request for sample pages

Industry Dynamics

Growth Drivers
The healthcare systems in developing countries such as India, China, Brazil, and Indonesia have seen tremendous growth in healthcare and infrastructure investments and are highly prioritizing cost-effectiveness and scalability to meet the rising demand from continuously expanding patient pool are the prominent factors projected to boost the growth and demand of the market. Furthermore, a rise in direct-to-consumer genetic testing, which allows individuals to have a deeper and more clear understanding of their genetic information without any need to involve their physicians, along with the growing awareness reading the links between genetics and diseases, which improve the evolution of patient’s health, are also likely to have a positive impact on the market growth.

Report Segmentation

The market is primarily segmented based on type, application, technology. end-use and region.

By Type

By Application

By Technology

By End-Use

By Region

  • Predictive Genetic Testing
  • Carrier Testing
  • Prenatal and Newborn Testing
  • Disease Diagnostic Testing
  • Pharmacogenomic Testing
  • Others
  • Cancer
  • Genetic Diseases
  • Cardiovascular Diseases
  • Rare Diseases
  • Infectious Diseases
  • Others
  • Next-Generation Sequencing
  • Real-Time PCR System
  • Others
  • Hospitals
  • Research & Development Laboratories
  • Diagnostic Centers
  • Others
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

Prenatal and newborn testing segment accounted for the largest market share in 2022

The prenatal and newborn testing segment accounted for a significant global market share in 2022 and is likely to retain its market position over the projected period. The rapid increase in mortality rates from various genetic diseases worldwide and rising government efforts to promote the latest prenatal testing are among the major factors influencing the segment market growth. Additionally, noninvasive prenatal testing has increased drastically over recent years because of its high level of safety and better accuracy compared to invasive diagnostic methods, which is also likely to lead to the demand and growth of the market.

Cancer segment is expected to witness fastest growth during the forecast period

The cancer segment is expected to witness the fastest growth during the anticipated period, which is highly accelerated by the ability of genetic testing to identify the risk of several types of cancers that might develop during an individual’s lifetime. These types of analysis are easily available to test various inherited variants and mutations in the DNA sequence that could lead to the excessive growth of cells and result in tumors or cancer. Furthermore, the rapidly growing burden of cancers globally and increased awareness among the global population regarding preventive diagnosis and personalized medicine are other factors projected to fuel the demand for enhanced testing services in the coming years.

For instance, according to the American Cancer Society, the total number of new cancer cases in the United States in 2022 is estimated to be around 1.9 million, and about 609,360 recent cancer deaths were diagnosed in the year. New cancer cases are projected to reach about 30.2 million by 2040.

Genetic Analysis Seg

Next-generation sequencing technology held the largest market share in 2022

The next-generation sequencing technology segment led the market with a significant market revenue share in 2022 because of the rise in the number of applications of next-generation sequencing in the healthcare sector and continuous advancements in sequencing platforms. In addition, with the ability of precise diagnosis and personalized medicine to increase the survival rates and reduce the financial burden on various national health insurance programs, the governments of many developed as well as developing countries are more likely to make huge investments in genome sciences, which in turn, having a positive impact on demand for NGS in such applications across the globe.

Research & development laboratories segment led the market in 2022

The research & development laboratories segment led the industry. It accounted for the majority market share in 2022, which is mainly driven by a wide range of tests offerings based on various specialties such as molecular genetic tests, chromosomal genetic tests, and biochemical genetic tests, along with the continuously increasing focus on developing new more effective services to provide a best comfortable experience to patients.

The diagnostic centers are likely to expand at a significant growth rate over the coming years, owing to the increasing prevalence of acute disorders and high penetration among the patients to go through the treatment at an early stage and mitigate the severity of the disease, which reduces the mortality rate.

The demand in Europe is expected to witness significant growth during the forecast period

The Europe region is projected to emerge as fastest growing region at a significant CAGR during the forecast period. The growth of the regional market can be largely attributed to increasing number of R&D initiatives that are being conducted by many countries including France, Sweden, UK, and Germany and the surge in the consumers spending capacity of their well-being and healthcare along with the high concentration of key market players towards the innovation of advanced novel genetic testing products.

The North America region dominated the global market in 2022, and is projected to maintain its dominance throughout the anticipated period, due to the continuous rise in the demand for personalized genetic testing services and high proliferation of various chronic and genetic disorders. In addition, the rising product approvals by the US Food and Drug Administration and presence of well-developed healthcare infrastructure and comparatively high healthcare spending in US as compared to other nations are key factors stimulating the demand for the product in the near future.

For instance, in April 2022, Invitae, a leading medical genetics company, announced the launch of its latest testing package for NDDs in children, that provides the genetic answers in a timely fashion. The package further includes a next-generation sequencing panel and analysis for fragile X-related disorders.

Genetic Analysis Reg

Competitive Insight

Some of the major players operating in the global market include Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation, Roche Ltd., Illumina, Myriad Genetics, Thermo Fisher Scientific, CSL Ltd., Eurofins Scientific, Siemens Healthiniers, PerkinElmer, Sysmex Corporation, Hologic, QIAGEN, Agilent Technologies, & Baylor Genetics.

Recent Developments

  • In October 2022, NHS England introduced its country-based genetic testing services to provide proactive measures for its babies & newborns. The newly developed service is likely to benefit over 1,000 children and babies in intensive care every year.
  • In July 2022, Inc., a leading diagnostic software company, announced the expansion of their testing services in both clinical and direct-to-customer in collaboration with Apollo Health Group. Apollo Health Group has streamlined its complex genetic testing workflows and eliminated error-prone paper-based processes.

Genetic Analysis Market Report Scope

Report Attributes


Market size value in 2024

USD 23.2 billion

Revenue forecast in 2032

USD 45.10 billion


8.60% from 2024– 2032

Base year


Historical data

2019 – 2022

Forecast period

2024– 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments covered

By Type, By Application, By Technology, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. HOFFMAN-La Roche Ltd., Illumina Inc., Myriad Genetics Inc., Thermo Fisher Scientific Inc., CSL Ltd., Eurofins Scientific, Siemens Healthinier, PerkinElmer Inc., Sysmex Corporation, Hologic Inc., QIAGEN, Agilent Technologies Inc., and Baylor Genetics.


The genetic analysis market report covering key segments are type, application, technology. end-use and region.

Genetic Analysis Market Size Worth $45.10 Billion By 2032.

The global genetic analysis market expected to grow at a CAGR of 8.64% during the forecast period.

Europe is leading the global market.

Key driving factors in genetic analysis market are increase in incidences of genetic disorders and cancer.